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Expression of CXCL10, a pro-inﬂammatory cytokine, correlates
positively with obesity and type 2 diabetes. Whether CXCL10
plays a role in NASH was unknown. We aimed to investigate
the functional and clinical impact of CXCL10 in NASH.
Methods: Cxcl10 gene-deleted (Cxcl10/) and C57BL/6 wild type
(WT) mice were fed a methionine- and choline-deﬁcient (MCD)
diet for 4 or 8 weeks. In other experiments, we injected neutral-
izing anti-CXCL10 mAb into MCD-fed WT mice. Human serum
was obtained from 147 patients with biopsy-proven non-alco-
holic fatty liver disease and 73 control subjects.
Results:WT mice, fed the MCD diet, developed steatohepatitis
with higher hepatic CXCL10 expression. Cxcl10/ mice were
refractory to MCD-induced steatohepatitis. We further revealed
that CXCL10 was associated with the induction of important
pro-inﬂammatory cytokines (TNF-a, IL-1b, and MCP-1) andJournal of Hepatology 20
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ammonium chloride potassium.activation of the NF-jB pathway. CXCL10 was linked to steatosis
through upregulation of the lipogenic factors SREBP-1c and LXR,
and also to oxidative stress (upregulation of CYP2E1 and C/EBPb).
Blockade of CXCL10 protected against hepatocyte injury in vitro
and against steatohepatitis development in mice. We further
investigated the clinical impact of CXCL10 and found circulating
and hepatic CXCL10 levels were signiﬁcantly higher in human
NASH. Importantly, the circulating CXCL10 level was correlated
with the degree of lobular inﬂammation and was an independent
risk factor for NASH patients.
Conclusions:We demonstrate for the ﬁrst time that CXCL10
plays a pivotal role in the pathogenesis of experimental steato-
hepatitis. CXCL10 maybe a potential non-invasive biomarker for
NASH patients.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Non-alcoholic fatty liver disease (NAFLD) has become increas-
ingly important worldwide due to changes in lifestyle and resul-
tant over-nutrition [1]. Non-alcoholic steatohepatitis (NASH) is a
severe form of NAFLD, characterized by necroinﬂammation and
lipid accumulation [2,3]. Little is known about the factors respon-
sible for the transition from benign steatosis to steatohepatitis in
NAFLD/NASH. As a consequence, apart from addressing lifestyle
issues, there are few effective interventions to treat patients with
NASH. The present concept about NASH pathogenesis is that
increased levels of toxic lipids, such as free fatty acids or free cho-
lesterol provide initiating and propagating mechanism for hepa-
tocellular injury and resultant inﬂammation. Inﬂammation may
result from oxidative stress and pro-inﬂammatory chemokines
and cytokines, which perpetuate liver injury and lead to ﬁbrosis
[4]. Identiﬁcation of the pro-inﬂammatory cytokines, which are
associated with lipotoxicity, may improve our understanding of14 vol. 61 j 1365–1375
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the pathogenesis of NASH, enabling the development of novel
pharmacological treatments.
One particularly important pro-inﬂammatory cytokine associ-
ated with lipotoxicity is the CXC motif chemokine ligand 10
(CXCL10), which recruits inﬂammatory cells to the site of tissue
damage [5,6]. CXCL10 has been implicated in the pathogenesis
of hepatitis C virus infection through interactions with the toll-
like receptor (TLR) 2 [7], and in hepatitis B virus-infection
through the nuclear factor-jB (NF-jB) pathway [8]. In various
types of liver injury, CXCL10 is secreted by hepatocytes in areas
of lobular inﬂammation [9,10] and neutralization of CXCL10
accelerates liver regeneration [11]. These data indicate a poten-
tial role for CXCL10 in the development of intrahepatic inﬂamma-
tion. Moreover, CXCL10 is upregulated in NASH patients [12] and
correlates positively with the incidence of obesity and type 2 dia-
betes [13,14]. These ﬁndings suggest that CXCL10 could be a piv-
otal molecule that facilitates transition from benign steatosis to
progressively hepatocellular damage and inﬂammation in
steatohepatitis.
We have recently reported that the anti-oxidant enzyme
heme oxygenase-1 protects against development of experimental
steatohepatitis in association with reduced production of CXCL10
[15]. In the present study, we ﬁrst investigated the functional role
of CXCL10 in the development of steatohepatitis using Cxcl10
gene-deleted mice, and further explored the molecular mecha-
nisms by which CXCL10 exerts its effects on inﬂammation, stea-
tosis, oxidative stress and apoptosis. We demonstrated by in vitro
and in vivo approaches that blockade of CXCL10 (neutralizing
anti-CXCL10 mAb) protected against steatohepatitis. In particu-
lar, we tested the clinical impact of CXCL10 in 147 patients with
biopsy-proven NAFLD and 73 control subjects and demonstrated
that circulating CXCL10 is an independent risk factor for patients
with NASH.Materials and methods
Animals and treatments
Age-matched male Cxcl10 knock out (Cxcl10/) and C57BL/6 wild type (WT) mice
(fromDr. AndrewD. Luster, HarvardMedical School) were fed either amethionine-
and choline-deﬁcient (MCD) diet or a control diet for 4 weeks to establish steato-
hepatitis, or for 8 weeks to establish ﬁbrosing steatohepatitis [15,16].
For CXCL10 neutralization experiments, male C57BL/6 WT mice were given
CXCL10-speciﬁc anti-CXCL10 mAb (R&D System, Minneapolis, MN) by intraperi-
toneal injection (50 lg in 200 lL PBS per mouse) at 12 h before MCD diet, and
then the injection was repeated every 2 days for 5 cycles [10,14]. Mice were also
given an isotype-matched rat IgG2A mAb (R&D System) at the same time as the
controls. In a separate experiment, anti-CXCL10 mAb or control mAb were sup-
plemented for 10 days under MCD diet after induction of steatohepatitis in mice
fed the MCD diet for 3 weeks. All animals received humane care and all animal
studies were performed in accordance with guidelines approved by the Animal
Experimentation Ethics Committee of the Chinese University of Hong Kong.
Mice were sacriﬁced as previously described [17]. Biochemical determination
of serum alanine aminotransferase (ALT) levels, triglycerides and lipid peroxida-
tion rates were performed. Liver histology, liver collagen content analysis, cyto-
kine proﬁling assay, cDNA expression array, nuclear DNA binding activity assay,
terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay,
ﬂuorescence activated cell sorting (FACS) analysis, qPCR and western blot were
performed.
Subjects and human sample collection
Serum samples were collected from 147 patients with biopsy-proven NAFLD and
73 healthy subjects as previously described [18,19]. Percutaneous liver
biopsy specimens were collected from 11 patients with NASH, 11 patients with1366 Journal of Hepatology 2014simple steatosis and 15 healthy controls in the Prince of Wales Hospital and
the Queen Mary Hospital, Hong Kong. All subjects had given written informed
consent and the study protocol was approved by the Clinical Research Ethics
Committee of the Chinese University of Hong Kong and the University of Hong
Kong.Statistical analysis
Differences between two groups were compared by the Mann-Whitney U test or
Student’s t test. Multiple group comparisons were made by the Kruskal-Wallis
test or one-way ANOVA. Spearman’s correlation coefﬁcient was used to estimate
the association of serum CXCL10 levels and several factors of interest, while mul-
tiple linear regression was used to determine the independent factors associated
with levels of CXCL10. Multiple logistic regression was performed to identify the
independent risk factors of NASH. A receiver operating characteristic (ROC) curve
analysis was conducted to assess the performance of CXCL10 in the prediction of
NAFLD/NASH. All statistical tests were performed using SPSS or GraphPad Soft-
ware. Data were expressed as mean ± standard deviation or median (interquartile
range [IQR]) and considered signiﬁcant at p <0.05.
Additional experimental procedures are provided in the Supplementary
Materials and methods section.Results
Hepatic CXCL10 expression is upregulated in experimental
steatohepatitis and is required for its development
To elucidate the role of CXCL10 in the development of steatohep-
atitis, Cxcl10/ and WT mice were fed control or MCD diets for
4 weeks. MCD-fedWTmice developed steatosis, ballooning hepa-
tocytes, scattered lobular inﬂammatory cell inﬁltration, and
inﬂammatory foci (Fig. 1A), consistent with steatohepatitis. This
was associated with increased hepatic CXCL10mRNA and protein
levels compared with mice fed a control diet (Fig. 1B), which
showed normal liver histology (Fig. 1A). Conversely, MCD-fed
Cxcl10/ mice showed signiﬁcant less steatosis (p <0.01) and
reduced inﬂammatory cell inﬁltration (p <0.01), as indicated by
steatosis and necroinﬂammatory scores (Fig. 1A). Consistent with
the histologic ﬁndings, measurement of serum ALT (p <0.0001),
hepatic lipid peroxide by the thiobarbituric acid reactive sub-
stances (TBARS) assay (p <0.01) and hepatic triglyceride contents
(p <0.01) revealed that loss of CXCL10 protected mice from MCD
diet-induced liver injury (Fig. 1C). The decreased lipid accumula-
tion in MCD-fed Cxcl10/ mice was conﬁrmed by Oil red O stain-
ing (Fig. 1A). Taken together, these data suggest that CXCL10
contributes to the development of steatohepatitis.CXCL10 is required for hepatic nutritional ﬁbrosis
To examine whether CXCL10 plays a role in hepatic nutritional
ﬁbrosis, Cxcl10/ mice and WT mice were fed with control or
MCD diet for 8 weeks. Intraparenchymal pericellular ﬁbrosis
developed from steatohepatitis in WT mice fed with MCD for
8 weeks as shown by Sirius Red staining (Fig. 1D), whilst,
MCD-fed Cxcl10/ mice showed impressively reduced amounts
of collagen ﬁbres (Fig. 1D). Morphometric analysis yielded con-
cordant results where the Sirius Red-stained collagen areas
were signiﬁcantly reduced in MCD-fed Cxcl10/ mice com-
pared to MCD-fed WT mice (p <0.05). Moreover, quantitation
of collagen by measuring hepatic hydroxyproline content sup-
ported the improvement of liver ﬁbrosis by CXCL10 deﬁciency
(Fig. 1D).vol. 61 j 1365–1375
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Fig. 1. Deﬁciency of CXCL10 attenuates experimental steatohepatitis. (A) Representative H&E staining (arrows, inﬂammatory cells) and Oil red O staining from 4-week
liver sections of Cxcl10/ and WT mice fed a control or MCD diet. (B) Hepatic CXCL10mRNA and protein levels in liver tissues of WT mice. (C) Serum ALT, total hepatic lipid
peroxide and liver triglyceride content in WT and Cxcl10/ mice fed control or MCD diet for 4 weeks. (D) Collagen deposition by Sirius Red staining and hydroxyproline
content of liver sections in mice fed a control or MCD diet for 8 weeks. Data are mean ± SD, n = 5–8/group. ⁄p <0.05, ⁄⁄p <0.001, ⁄⁄⁄p <0.0001 vs. same genotype mice fed
control diet. #p <0.01 vs. WT mice fed MCD diet.
JOURNAL OF HEPATOLOGYCXCL10 induces hepatic chemokines, cytokines and other
proinﬂammatory molecules
We next determined the mechanisms of CXCL10 in regulating
hepatic inﬂammation by analysing chemokines and cytokines
involved in inﬂammation and cell recruitment. In keeping with
the improved liver histology and reduction of liver injury, lossJournal of Hepatology 2014of CXCL10 signiﬁcantly reduced the production of key pro-
inﬂammatory chemokines and cytokines such as tumor necrosis
factor-a (TNF-a), interleukin (IL)-1b, and monocyte chemoattrac-
tant protein-1 (MCP-1), as indicated initially by a cytokine proﬁl-
ing assay (Fig. 2A) and conﬁrmed by qRT-PCR (Supplementary
Fig. 1A–C). We then conducted a cDNA expression assay to iden-
tify molecules involved in CXCL10-mediated pathogenesis ofvol. 61 j 1365–1375 1367
WT
Cxcl10-/-
WT
Cxcl10-/-
Control
MCD
Cxcl10-/-WT
Cxcl10-/-WT
Cx
cl1
0-
/-W
T
Cx
cl1
0-
/-W
T
Cx
cl1
0-
/-W
T
Cx
cl1
0-
/-W
T
Cx
cl1
0-
/-W
T
Cx
cl1
0-
/-W
T
Cxcl10-/-WT
p <0.05
p <0.0001 p <0.0001
p <0.0001
p <0.05
p <0.05
p <0.01
0
1
2
3
0
10
20
30
Cxcl10-/-WTCxcl10-/-WT Cxcl10-/-WT
p <0.05
0
1
2
3
   
   
  
TN
F-
α 
(p
g/
m
g 
pr
ot
ei
n)
IL
-1
β 
(p
g/
m
g 
pr
ot
ei
n)
** *
M
C
P
-1
 (p
g/
m
g 
pr
ot
ei
n)
  
**
A
***
p-NFκB p65
p-N
Fκ
B 
p6
5
GAPDH
       R
el
at
iv
e 
pr
ot
ei
n 
le
ve
ls
B
**
CYP2E1
GAPDH
D
R
el
at
iv
e 
C
Y
P
2E
1 
m
R
N
A
SR
EB
P-
1c
SC
D-
1
C
S
R
E
B
P
-1
 b
in
di
ng
 a
ct
iv
ity
 (O
D
45
0 
nm
)  
C
/E
B
P 
bi
nd
in
g 
ac
tiv
ity
 (O
D
45
0 
nm
)  
R
el
at
iv
e 
C
/E
B
P
β 
pr
ot
ei
n 
R
el
at
iv
e 
 C
Y
P
2E
1 
pr
ot
ei
n 
 
0.0  
0.5  
1.0  
1.5  
0.0 
0.5 
1.0 
1.5 
0.0 
0.5 
1.0 
1.5
2.0
 
0.0 
0.5 
1.0 
1.5
2.0
 
R
el
at
iv
e 
pr
ot
ei
n 
le
ve
ls p <0.05
p <0.05
p <0.05
p <0.05p <0.05
p <0.01
p <0.01
p <0.01
E F
G
0
20
40
60
TU
N
E
L 
po
si
tiv
e 
ce
lls
 (‰
) 
 Cleaved
caspase3
GAPDH
 *
Control MCD
WT
Control MCD
R
el
at
iv
e 
cl
ea
ve
d
ca
sp
as
e 
3 
pr
ot
ei
n 
TU
N
E
L 
st
ai
ni
ng
 
0.15 
0.10 
0.05 
0.00 
15
0
10
5
p-NFκB p50
p-N
Fκ
B 
p5
0
IκBα
IκB
αN
Fκ
B
  b
in
di
ng
 a
ct
iv
ity
(O
D
45
0 
nm
)
0.6
0.4
0.2
0.0
2.5
2.0
1.5
1.0
0.5
0.0
Cxcl10-/-WT
   
SREBP-1c
GAPDH
SCD-1
Cxcl10-/-WT
Lamin A
 Nuclear 
C/EBPβ  
Cxcl10-/-WT
Cxcl10-/-
Cxcl10-/-
WT
Control
MCD
Control
MCD
1.5
1.0
0.5
0.0
Fig. 2. CXCL10 induces steatohepatitis through hepatic inﬂammatory molecules, lipogenic factors and oxidative stress. (A) Hepatic TNF-a, IL-1b, and MCP-1 protein
levels in mice fed control or MCD diet. (B) NF-jB nuclear binding activity and protein levels of phosphorylated NF-jB subunits p65, p50 and NF-jB suppressor IjBa, (C)
protein levels of SREBP-1c, SCD1 and nuclear SREBP-1c DNA binding activity, (D) protein levels of C/EBPb and nuclear C/EBP DNA binding activity, (E) hepatic CYP2E1mRNA
and protein expression in MCD-fed mice. (F) TUNEL positive cells per 1000 cells and cleaved caspase 3 expression in liver tissues. (G) Schematic diagram for the
mechanisms of CXCL10 in the promotion of steatohepatitis. ⁄p <0.05, ⁄⁄p <0.0001 vs. same genotype mice fed control diet.
Research Articlesteatohepatitis using an additional panel of inﬂammatory
response factors and comparing their expression in MCD-fed
Cxcl10/ and WT mouse livers. Loss of CXCL10 was associated
with substantially increased expression of CXCL6 (63.2-fold),1368 Journal of Hepatology 2014CXCL9 (27.7-fold), E-selectin (SELE), IFN-c, oxidative stress-associ-
ated transcription factor CCAAT/enhancer binding protein beta
(C/EBPb), and NF-jB signalling components including IL-6 (24.1-
fold), CCL22 (13.2-fold), TLR9, CXCL5 and cyclooxygenase-2vol. 61 j 1365–1375
Table 1. The effect of CXCL10 on gene expression proﬁles of inﬂammatory
response in mice liver tissues.
Gene name Fold change† Gene function
CXCL6 63.2 Pro-inflammatory cytokine
CXCL9 27.7 Inflammatory response
E-Selectin 7.4 Inflammatory response
IFN-γ 5.3 Pro-inflammatory cytokine
C/EBPβ 4.2 Oxidative stress
IL-6 24.1 Acute-phase response
CCL22 13.2 Inflammatory response
TLR9 4.2 Inflammatory response
CXCL5 2.8 Inflammatory response
COX-2 2.7 Acute-phase response
MCD-fed WT mice vs. MCD-fed Cxcl10/ mice.
JOURNAL OF HEPATOLOGY(COX-2) (Table 1). These data support that CXCL10 plays a critical
role in liver inﬂammation.
CXCL10 activates NF-jB
Given the crucial role of NF-jB signalling in the pathogenesis of
steatohepatitis [20,21], we examined whether CXCL10 played any
role in modulation of this pathway in steatohepatitis. NF-jB
nuclear binding activity was increased in MCD-fedWT mice com-
pared with control diet (p <0.0001), but not in MCD-fed Cxcl10/
mice (Fig. 2B). This was conﬁrmed by enhanced levels of phos-
phorylated NF-jB subunits p65 and p50, decreased cytosolic
NF-jB suppressor IjBa (Fig. 2B) and upregulation of NF-jB
downstream factor intercellular adhesion molecule-1 (ICAM-1)
in MCD-fed WT mice compared to corresponding Cxcl10/ mice
(Supplementary Fig. 1D). Our ﬁndings indicate that CXCL10
employs NF-jB signalling to mediate inﬂammation in
steatohepatitis.
CXCL10 contributes to hepatic steatosis by inducing lipogenic genes
To seek an explanation for the reason why deletion of CXCL10
caused less steatosis, we assessed hepatic expression of lipogenic
regulators and genes, including liver X receptor (LXR)a, LXRb, ste-
rol regulatory element binding protein isoform 1c (SREBP-1c),
carbohydrate response element binding protein (ChREBP) and
stearoyl-CoA desaturase isoform-1 (SCD-1) as well as genes and
regulators of hepatic fatty acid oxidation, such as adiponectin,
peroxisome proliferator-activated receptor-alpha and its down-
stream target molecules, acyl-CoA oxidase, long-chain acyl-CoA
dehydrogenase, cytochrome P450 (CYP) 4a10 and 4a14. Com-
pared to MCD-fed WT mice, MCD-fed Cxcl10/ mice showed sig-
niﬁcantly lower mRNA expression of LXRa, LXRb, SREBP-1c,
ChREBP, and SCD-1 (Table 2). Western blot conﬁrmed the down-
regulation of SREBP-1c and SCD-1 protein expression in liver
lysates (Fig. 2C). Concomitantly, the nuclear DNA-binding activity
of SREBP-1c was decreased in Cxcl10/ mice (Fig. 2C). Expression
of lipolytic genes, regulating fatty acid oxidation, was similar
between Cxcl10/ and WT mice fed MCD (Table 2). These ﬁnd-
ings indicate that CXCL10 either directly or indirectly (such as
via MCP-1) can inﬂuence hepatic lipogenesis, thereby contribut-
ing to steatosis as well as its inﬂammatory consequences.Journal of Hepatology 2014CXCL10 contributes to oxidative stress through CYP2E1 and C/EBPb
In addition to the accumulation of hepatic triglycerides in
response to choline deﬁciency and lipogenesis [22,23], and
impaired antioxidant defences in response to methionine deﬁ-
ciency, induction of CYP2E1 (or CYP4A) [24] and C/EBPb [17]
may induce oxidative stress in the MCD model of steatohepatitis.
To establish whether the latter factors contributed to the protec-
tion against steatohepatitis afforded by CXCL10 deletion, we eval-
uated the levels of C/EBPb and CYP2E1. Both C/EBPb and CYP2E1
mRNA and protein expression were signiﬁcantly less in MCD-fed
Cxcl10/ compared to corresponding WT mice (Fig. 2D and E,
Table 1). Nuclear C/EBP DNA-binding activity was also decreased
in Cxcl10/ mice (Fig. 2D). Thus, CXCL10 could contribute to
hepatic oxidative stress in steatohepatitis by regulating C/EBP
and its downstream target CYP2E1.
CXCL10 contributes to hepatic apoptosis
As the elevation of apoptotic cell death is closely associated with
the severity of NASH [25], we assessed the role of CXCL10 in reg-
ulating hepatic apoptosis in steatohepatitis by TUNEL assay. We
found that TUNEL-positive cells were signiﬁcantly less in
Cxcl10/ mice compared to WT mice fed MCD (0.94% vs. 4.56%,
p <0.01) (Fig. 2F). Consistent with the impaired apoptosis, the
protein expression of the active form of the apoptosis regulator
caspase-3 was signiﬁcantly downregulated in Cxcl10/ mice
compared with WT mice (Fig. 2F).
Phenotypic analysis of immune cells in the spleen and peripheral
blood of Cxcl10/ and WT mice
In order to investigate the major immune cell populations in
CXCL10/ and WT mice, we performed FACS analysis in the
spleen and peripheral blood. Consistent with a previous report
of Cxcl10/ mice [26], the frequencies of B cells (CD19+CD3),
T cells (CD3+CD19), NK cells (NK1.1+CD3), NKT cells
(NK1.1+CD3+), macrophages (CD11b+F4/80+) and neutrophils
(CD11b+Ly6G+) in the spleen and peripheral blood of Cxcl10/
mice were not changed compared to WT mice under MCD or con-
trol diet (Supplementary Figs. 2 and 3). Only a slight reduction of
CD8+ T lymphocytes (CD8+CD4) was observed in the spleen of
MCD-fed Cxcl10/ mice compared to WT mice fed with the same
diet (34.3 ± 2.26 vs. 38.5 ± 1.34) (Supplementary Fig. 2).
Inactivation of CXCL10 by anti-CXCL10 mAb antagonizes
MCD-induced steatohepatitis
The above results indicate essential and multiple roles of CXCL10
in steatohepatitis pathogenesis. If this is the case, speciﬁc CXCL10
inhibition should dampen or abrogate the development of this
type of liver pathology. To test this, we ﬁrst examined the func-
tional effect of an anti-CXCL10 monoclonal antibody (mAb) on
steatosis and injury to hepatocyte-derived cells in vitro. As
reported [15,17], incubation of the immortalized murine hepato-
cyte cell line AML-12 with MCD medium for 24 h increased med-
ium ALT, cellular triglyceride and oxidative stress, detected by
TBARS and lipid hydroperoxide assays (Supplementary Fig. 4).
Conversely, anti-CXCL10 mAb added to AML-12 cells incubated
in MCD medium signiﬁcantly reduced medium ALT, cellular
triglycerides, cellular TBARS and lipid hydroperoxide levelsvol. 61 j 1365–1375 1369
Table 2. Hepatic mRNA expression of genes involved in fatty acid regulation in Cxcl10/ mice.
Gene WT mice Cxcl10-/- mice
Control MCD Control MCD
Lipogenic genes
LXRα 1.05 ± 0.33 1.52 ± 0.31** 0.99 ± 0.12 0.97 ± 0.23##
LXRβ 1.05 ± 0.30 1.91 ± 0.68** 1.28 ± 0.31 1.30 ± 0.34#
SREBP-1c 1.01 ± 0.16 0.63 ± 0.30* 0.53 ± 0.23 0.30 ± 0.11#
ChREBP 1.01 ± 0.18 0.66 ± 0.26* 1.25 ± 0.31 0.32 ± 0.08***#
SCD-1 1.035 ± 0.33 0.012 ± 0.006*** 0.570 ± 0.213 0.006 ± 0.004***#
Lipolytic genes
Adiponectin 1.44 ± 1.09 0.30 ± 0.29 2.15 ± 0.97 1.08 ± 0.91
PPARα 1.01 ± 0.14 0.69 ± 0.23* 1.17 ± 0.14 0.59 ± 0.09***
ACO 1.04 ± 0.35 0.28 ± 0.07** 1.27 ± 0.49 0.29 ± 0.06
LCAD 1.04 ± 0.31 1.19 ± 0.53 0.74 ± 0.29 0.71 ± 0.22
CYP4A10 0.91 ± 0.55 2.79 ± 1.20* 1.30 ± 0.68 1.46 ± 0.61
CYP4A14 2.03 ± 2.45 79.5 ± 34.2*** 1.69 ± 1.16 50.2 ± 25.4**
Speciﬁc mRNA expression values were normalized to the expression of GAPDH. Data are mean ± SD, n = 5–8/group. ⁄p <0.05, ⁄⁄p <0.01, ⁄⁄⁄p <0.0001 compared with
corresponding mice fed control diet. #p <0.05, ##p <0.0001 compared with WT mice fed the MCD diet.
Research Articlecompared to AML-12 cells in MCD medium exposed to control
IgG2A mAb (Supplementary Fig. 4).
We next examinedwhether administration of the anti-CXCL10
mAb by intraperitoneal injection could prevent MCD-induced
steatohepatitis in vivo. Administration of the anti-CXCL10 mAb
to MCD-fed WT mice reduced steatosis and inﬂammatory cell
inﬁltration (Fig. 3A), with concordant reduction of serum ALT,
hepatic triglyceride and lipid hydroperoxide levels (Fig. 3B) com-
pared to MCD-fed mice administered control mAb. Likewise,
CXCL10 neutralization suppressed NF-jB binding activity
(p <0.01), and reduced the expression of phosphorylated NF-jB
subunits p65 and p50 (p <0.05) and ICAM-1 mRNA (p <0.05)
(Fig. 3C). Moreover, blocking CXCL10 signiﬁcantly decreased the
levels of CYP2E1 (p <0.01) and SREBP-1c (p <0.05) (Fig. 3D).
After conﬁrming a preventive effect on steatohepatitis, we
further examined whether CXCL10 neutralization could treat ste-
atohepatitis after it has been established. After induction of ste-
atohepatitis in mice fed the MCD diet for 3 weeks, anti-CXCL10
mAb or control mAb was supplemented for 10 days under MCD
diet. Histological analysis of livers by H&E and Oil red O staining
showed signiﬁcantly reduced lipid accumulation and inﬂamma-
tory cell inﬁltration in MCD-fed mice treated with anti-CXCL10
mAb (Fig. 3E). Anti-CXCL10 mAb treatment in MCD-fed mice also
signiﬁcantly decreased hepatic triglyceride and lipid peroxide
levels compared to MCD-fed mice administrated with control
mAb (Fig. 3F). Moreover, CXCL10 neutralization suppressed hepa-
tic TNF-a (p <0.05) and ICAM-1 (p <0.05) mRNA expression
(Fig. 3G). These data added further weight to the effects of
CXCL10 in mediating inﬂammation, oxidative stress and steatosis
in the evolution of steatohepatitis.
CXCL10 is associated with lobular inﬂammation and acts as an
independent risk factor of human NASH
Since the MCD model reﬂects pathologically severe steatohepati-
tis with choline and amino acid nutritional deﬁciency and a con-
text of ‘‘lipid trapping’’ in the liver with severe oxidative stress, it
remains important to establish whether human NASH related to1370 Journal of Hepatology 2014over-nutrition is also associated with increased liver expression
and circulating levels of CXCL10. To this end, we assayed CXCL10
mRNA in liver biopsy from 15 control subjects and 22 NAFLD
patients (11 simple steatosis patients and 11 human NASH
patients). The results showed that hepatic CXCL10 mRNA levels
were signiﬁcantly higher in primary NASH tissue compared to
simple steatosis (p <0.05) and normal controls (p <0.001)
(Fig. 4A), inferring that hepatic CXCL10 production is prominent
in patients with NASH.
We next ascertained the clinical impact of CXCL10 in NASH
patients. We enrolled a well-established prospective cohort of
73 control subjects without fatty liver measured by proton-
magnetic resonance spectroscopy and 147 age and gender
matched biopsy-proven NAFLD patients, 69 of whom were
diagnosed as NASH [18,19]. We found that serum CXCL10 was
signiﬁcantly increased in a stepwise fashion from control subjects
(111 [IQR: 98–146] pg/ml), patients with simple steatosis (170
[133–225] pg/ml) to patients with NASH (248 [154–310] pg/ml)
(Fig. 4B, all p <0.0001). In NAFLD patients (simple steatosis and
NASH), CXCL10 was signiﬁcantly and positively correlated with
lobular inﬂammation (rho: 0.26, p = 0.002) and hepatocyte bal-
looning degeneration (rho: 0.24, p = 0.004), which are two major
histological features of NASH (Table 3). Multivariable linear
regression analysis also demonstrated that the serum CXCL10
level was positively associated with lobular inﬂammation (Beta:
47.9; 95% CI: 15.0–80.8; p = 0.005) and ballooning (Beta: 51.1;
95% CI: 20.0–82.1; p = 0.001) independent of metabolic syn-
drome, body mass index (BMI), ALT, triglyceride, fasting glucose
and cholesterol. Moreover, we performed a multivariate logistic
regression analysis on these subjects and identiﬁed that CXCL10
was an independent risk factor for NASH in NAFLD patients (OR:
1.008, 95% CI: 1.004–1.013, p <0.001) (Table 4, with factors
included in the regression model listed).
CXCL10 is a potential biomarker for the clinical diagnosis of NASH
To evaluate the utility of CXCL10 as a biomarker in the diagnosis
of NAFLD and NASH, a ROC curve was constructed. CXCL10vol. 61 j 1365–1375
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JOURNAL OF HEPATOLOGYexhibited a high overall accuracy in discriminating NAFLD from
control subjects with the area under the receiver operating char-
acteristic curve (AUROC) of 0.81 (95% CI: 0.75–0.87) (Fig. 4C). InJournal of Hepatology 2014NAFLD patients, CXCL10 had a moderate accuracy with the
AUROC of 0.68 (95% CI: 0.59–0.77) in discriminating NASH from
simple steatosis (Fig. 4C). If control subjects were also added tovol. 61 j 1365–1375 1371
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Table 3. Correlations with CXCL10 in NAFLD patients.
CXCL10
rho p value‡
Age 0.16 0.062
BMI 0.07 0.408
Total cholesterol 0.09 0.304
Triglyceride 0.09 0.286
Steatosis 0.15 0.070
0.26 0.002
Ballooning
Lobular inflammation
0.24 0.004
Fibrosis 0.25 0.002
p value corresponds to Ho: rho = 0.
Table 4. Multivariable analysis for independent risk factors for NASH in
NAFLD patients.
OR 95% CI p value
CXCL10 1.008§ 1.004-1.013 <0.001
Metabolic syndrome 3.083 1.203-7.903 0.019
Variables entered in the regression model: CXCL10, gender, age, body mass index
(BMI), metabolic syndrome, alanine aminotransferase (ALT), fasting glucose, tri-
glyceride, low density lipoprotein-cholesterol (LDL-c), glycated haemoglobin
(HbA1c).
§For every 1 unit increase of CXCL10 level.
Research Articlethe analysis, the AUROC of diagnosing NASH increased to 0.77
(95% CI: 0.70–0.84) (Fig. 4C). Thus, CXCL10 can be a novel bio-
marker for the clinical diagnosis of NAFLD and NASH.Discussion
The ﬁrst novel ﬁnding in these studies is that Cxcl10/ mice
administrated with MCD diet showed signiﬁcantly attenuated
steatohepatitis compared with WT mice fed the same diet; these
ﬁndings were corroborated by improved liver histology, lowered
serum ALT, and hepatic triglyceride content. Moreover, CXCL10
deletion was associated with a signiﬁcant reduction of intrahe-
patic oxidative stress, as indicated by decreased lipid peroxide
levels. This change was clearly associated with the attenuation1372 Journal of Hepatology 2014of hepatic inﬂammation. In addition, CXCL10 deﬁciency confers
protection from hepatic nutritional ﬁbrosis. Our data provide
the ﬁrst evidence that CXCL10 may contribute to lipogenesis,
thereby inﬂuencing steatosis and possibly lipotoxicity, as well
as hepatocellular injury and perpetuation of liver inﬂammation
in steatohepatitis, at least in the MCD model.
The molecular mechanisms by which CXCL10 exerts its broad
range of functions in steatohepatitis were subsequently studied.
As a key pro-inﬂammatory cytokine, CXCL10 often ampliﬁes the
effects of other cytokines [5]. We therefore evaluated the effect
of CXCL10 on other potential cytokines in steatohepatitis and
showed that CXCL10 was associated with induction of TNF-a,
IL-1b, and MCP-1. TNF-a is a key inﬂammatory factor involved
in the development of human NASH [27] and experimental ste-
atohepatitis [28]. TNF-a can activate neutrophils, cause insulin
resistance and promote NASH development. TNF-a and IL-1b
are able to induce MCP-1 in vitro, suggesting that these cytokines
are functionally related [29]. MCP-1 is also an important mole-
cule in NASH as it may bridge inﬂammatory responses with the
induction of insulin resistance [30]. Moreover, MCP-1 can stimu-
late lipogenesis to promote steatosis in the liver, allowing inﬂam-
mation to exacerbate steatosis [4]. This suggests that CXCL10
induces cytokine expression, leading to the development of
steatohepatitis.
We further characterized the inﬂammatory factors, regulated
by CXCL10 in steatohepatitis, by a cDNA array covering 84 well-
known inﬂammatory genes. Our results show that pro-inﬂamma-
tory factors, including IFN-c, TLR9, CXCL9, IL-6, SELE, CXCL6, CCL22,
CXCL5, and COX-2, were signiﬁcantly higher in WT mice than in
Cxcl10/ mice fed with MCD. Each of these molecules could
amplify the inﬂammatory recruitment in steatohepatitis. To be
speciﬁc, IFN-c is a major inducer of CXCL10 related to NASH
pathogenesis [31]; TLR9 activates IFN regulatory factors that
induce production of IL-1b, leading to NASH development in
mouse model [32]; CXCL9, induced by IFN-c, is increased in the
livers of patients with NASH [33], while IL-6 is a key inﬂamma-
tory factor involved in NASH development [34]. Serum levels of
E-selectin (SELE) are also higher in patients with NASH similar
to those of IL-6 [35]. CXCL6 is associated with the severity of
hepatic inﬂammation in NAFLD patients and it can be used for
predicting NASH progression [36]. Similarly, CCL22 and CXCL5,
two small chemokines, are serum markers for NASH and the
related obesity and metabolic syndrome [37]. Finally, COX-2,vol. 61 j 1365–1375
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another pro-inﬂammatory mediator, plays an important role in
metabolic forms of steatohepatitis as reported earlier by us
[28]. In addition to IFN-c and TLR9, a close correlation between
CXCL10 and TNF-a, MCP-1, IL-6 has been well documented
[38,39]. Collectively, these data suggested that induction of pro-
inﬂammatory cytokines and key inﬂammatory factors by CXCL10
is part of a mechanism for the inﬂammatory recruitment in MCD-
induced steatohepatitis.
An important observation in the present study is that the
majority of the above cytokines and inﬂammatory factors are reg-
ulated by NF-jB signalling (Fig. 2G). TNF-a is a potent activator of
NF-jB, and in turn activated NF-jB induces TNF-a expression
[40]. TLR9 and IL-6 can also activate NF-jB [32], while ICAM-1,
CCL22, COX-2, IL-1b, MCP-1, and CXCL5 are downstream effectors
of NF-jB activation (Fig. 2G) [20]. These data, when combined
with the previous ﬁnding that NF-jB is a key regulator of early
hepatic inﬂammatory recruitment and liver injury in NASH
[21], implicate a collaborative interaction of CXCL10 and NF-jB
to promote steatohepatitis. Therefore, CXCL10 may act as a lipo-
toxic molecule that activates NF-jB and its downstream inﬂam-
matory effectors to induce hepatocyte apoptosis and liver
injury, leading to the progression of steatohepatitis.
The underlying causes of hepatic triglyceride accumulation in
steatosis include enhanced uptake and synthesis of fatty acids,
and inhibition of fatty acid oxidation. In our experimental steato-
hepatitis model, knockout of CXCL10 signiﬁcantly reduced hepa-
tic triglyceride content and steatosis (Fig. 1A and C). This
reduction was associated with reduced activity of SREBP-1c and
downregulation of SREBP-1c, ChREBP, LXRs, and SCD-1 (Fig. 2
and Table 2), which are involved in de novo fatty acid synthesis.
In addition to SREBP-1c and ChREBP, LXR is a major transcrip-
tional activator for lipogenesis [41]; it modulates the expression
of SREBP-1c through directly binding to the promoter of SREBP-
1c. LXR also induces the transcription of the lipogenic genes
SCD-1 and ChREBP [41]. Thus, the likely pathways by which
CXCL10 promotes hepatic steatosis include the upregulation of
key fatty acid synthesis genes that promote fatty acid synthesis
(Fig. 2G).
It is of general agreement that oxidative stress facilitates the
advancement of steatosis to steatohepatitis. Among the common
mediators of oxidative stress [42], CYP2E1 is an oxido-reductase
that can promote NASH development by inducing oxidative/
nitrosative stress, protein modiﬁcations, inﬂammation and insu-
lin resistance [43]. Consistent with this, we conﬁrmed earlier
ﬁndings [17,24] that CYP2E1 expression is upregulated in MCD-
induced steatohepatitis. Importantly, we showed that deletion
of CXCL10 completely abolished the MCD-dependent stimulation
of CYP2E1, and signiﬁcantly reduced the expression of its tran-
scriptional activator C/EBPb (Fig. 2D–E). These data were in accor-
dance with the lower level of CYP2E1 in MCD-fed Cebpb/ mice
compared with MCD-fed WT mice [41], and demonstrate that
CXCL10 can act upstream of C/EBPb and CYP2E1 to modulate
oxidative stress.
If CXCL10 plays a key part in the pathogenesis of steatohepa-
titis, it would be important to establish that its functional block-
ade ameliorates the severity of steatohepatitis. To test this, we
used anti-CXCL10 mAb to neutralize CXCL10 in vitro. Such neu-
tralization caused a dose-dependent decrease in triglyceride
secretion and ALT release, together with a concomitant suppres-
sion of cellular oxidative stress in AML12 hepatocytes (Supple-
mentary Fig. 4). Moreover, anti-CXCL10 mAb ameliorated theJournal of Hepatology 2014severity of fatty liver disease in MCD-fed mice. In the present
work, CXCL10 neutralization using anti-CXCL10 mAb in mice
showed signiﬁcant improvements in the prevention and regres-
sion of steatohepatitis (Fig. 3). These effects were associated with
reduced hepatic triglyceride and lipid peroxide levels (Fig. 3).
Thus, CXCL10 is a potential target for the prevention and treat-
ment of steatohepatitis.
These mechanistic ﬁndings of CXCL10 in the evolution of
experimental steatohepatitis encouraged us to explore the clini-
cal impact of CXCL10 in patients with NAFLD and NASH. We ﬁrst
demonstrated that CXCL10 was signiﬁcantly upregulated both in
liver and serum samples of NASH patients. Moreover, the circu-
lating level of CXCL10 in NASH patients was associated with lob-
ular inﬂammation, which is supported by a previous study that
showed that increased CXCL10 levels were correlated with the
degree of chronic liver inﬂammatory damage caused by hepatitis
C virus infection [9]. Early identiﬁcation of patients with NASH
may allow intervention that may alter the course of the disease.
Currently, liver biopsy remains the standard method for the diag-
nosis of NASH and differentiation from simple steatosis. How-
ever, biopsy is an invasive diagnostic procedure that has been
associated with sampling error and observer variability. Thus,
the development of a non-invasive test is paramount to the man-
agement of NASH. To date, there are no reliable serologic tests for
the identiﬁcation of NASH. Identiﬁcation of such biomarker
would aid clinicians in the identiﬁcation of patients with NASH,
and allow for non-invasive frequent monitoring of disease pro-
gression and response to therapy. Building on the signiﬁcantly
elevated CXCL10 level in NASH patients, we tested the clinical
utility of CXCL10 as a serologic biomarker for the diagnosis of
NASH. Base on a multivariate Cox regression analyses in a study
cohort of 147 NAFLD patients and 73 control subjects, CXCL10
was revealed to be a novel risk factor of NASH independent of
metabolic syndrome, ALT, diabetes and triglycerides (Table 4).
Moreover, the AUROC indicated an overall accuracy of 81% to
diagnose NAFLD and an accuracy of 77% to diagnose NASH, sug-
gesting that circulating CXCL10 production could be regarded
as a valuable new diagnostic factor for NAFLD and NASH. How-
ever, it should be noted that a few prediction models such as
the NAFLD ﬁbrosis score have also been developed to predict
advanced ﬁbrosis [44,45], These scores are comprised of predict-
ing factors of ﬁbrosis such as age, BMI and metabolic factors.
While it is interesting that CXCL10 may serve as a marker of
NASH, the ﬁnding warrants independent validation. Furthermore,
it would also be important to explore its role in conjunction with
other predicting factors to improve the diagnosis.
The MCD diet model is a classic and widely adopted dietary
model for studying NASH. It can induce hepatic steatohepatitis
with inﬂammation, oxidative stress, mitochondrial DNA damage,
apoptosis and ﬁbrosis [46]. Therefore, it is considered as one of
the best-established models for studying NASH-associated
inﬂammation, oxidative stress and ﬁbrosis. However, it does
not fully manifest all human NASH features. Mice fed with
MCD diet lose weight instead of being obese and lack insulin
resistance [47]. In the future, high-fat and high-fructose model
(also termed as American Lifestyle-Induced Obesity Syndrome
[ALIOS]), which may result in an obese animal with severe stea-
tosis, inﬂammation, oxidative stress and insulin resistance at
16 weeks [46,48], could be used to support our ﬁndings.
In conclusion, these observations and interventions demon-
strate for the ﬁrst time that CXCL10 plays an essential role invol. 61 j 1365–1375 1373
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the development of steatohepatitis in the context of fatty liver
disease. Further, the mechanism of this effect is through regula-
tion of lipogenesis and oxidative stress either directly or indi-
rectly via pathway modulation and pro-inﬂammatory signalling,
altering the expression of other key chemokines, cytokines and
pro-inﬂammatory molecules. Circulating CXCL10 may be a poten-
tial biomarker for patients with NAFLD and NASH.Financial support
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